Insider Transactions Reported by 19 Insiders of Entera Bio Ltd.

Symbol: ENTX on Nasdaq
Location: Jerusalem

Key facts

ENTX - Entera Bio Ltd. has 19 insiders with reported activity on this page.
Net insider value flow over the last year: +$140,882.
Recent transaction rows are available for direct filing-level review.

Change

Buy value: $140,882; sell value: $0.
Net share flow: +101,500.

Research use

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Evidence

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Net insider flow leans to buying over the last 12 months. Net value: +$140,882.

Buys

$140,882

Shares: 101,500

Insiders: 5

Sells

Shares: 0

Insiders: 0

Net

+$140,882

Shares: +101,500

Insiders: 5

Window (months)	Buy shares	Buy $	Sell $	Net $
0-3	30,000	$38,300	$0	+$38,300
3-6	71,500	$102,582	$0	+$102,582
6-9	0	$0	$0	$0
9-12	0	$0	$0	$0

Entera Bio Ltd. executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
Knoll Capital Management, LLC	10%+ Owner	$5,534,275			Mixed	14 Nov 2024
Gerald M. Lieberman	Director	$823,723			Mixed	01 Jan 2026
Miranda Jayne Toledano	Chief Executive Officer, Director	$772,186	+$19,912	+2.6%	Filing P/S	29 Dec 2025
Phillip Schwartz	President of R&D, Director	$601,336			Mixed	20 Jan 2022
Sean Ellis	Director	$231,360	+$34,620	+18%	Filing P/S	05 Mar 2026
Gregory Burshtein	Chief of R&D	$209,826			Median	07 May 2026
Dana Yaacov-Garbeli	Chief Financial Officer	$190,299			Median	07 May 2026
Yonatan Malca	Director	$185,024			Mixed	01 Jan 2026
Hillel Galitzer	Chief Operating Officer	$181,558			Median	07 May 2026
Gerald M. Ostrov	Director	$180,820			Mixed	01 Jan 2026
Geno J. Germano	Director	$52,000	+$55,800	+107%	Filing P/S	09 Mar 2026
Steven D. Rubin	Director	$22,350	+$19,450	+671%	Filing P/S	12 Feb 2026
Spiros Jamas	Chief Executive Officer	$9,900			Mixed	18 Jan 2022
Ramesh Ratan	U.S.based CFO	$9,900			Mixed	19 Jan 2022
Haya Taitel	Director		+$11,100		Mixed	10 Feb 2026
Ron Mayron	Director				Mixed	01 Jan 2024
Roger Garceau	Director				Mixed	01 Jan 2024
Leslie Velka Gautam	Chief Business Officer				Mixed	08 May 2025
Arthur C. Santora II	Chief Medical Officer				Mixed	24 Apr 2023

Top shareholders of Entera Bio Ltd. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
OPKO HEALTH, INC.	13D/G	—	8.1%	3,685,226	$8,660,281	$0	16 Mar 2025	13D/G
Point72 Asset Management, L.P.	13D/G 13F	Company	2.6%	1,183,116	$2,271,583	-$2,915,412	30 Sep 2025	13D/G 13F
Geno J. Germano	3/4/5	Director	0.09%	40,000	$52,000	+$55,800	09 Mar 2026	3/4/5
Steven D. Rubin	3/4/5	Director	0.03%	15,000	$22,350	+$19,450	12 Feb 2026	3/4/5
Knoll Capital Management, LLC	13F 3/4/5	Company · 10%+ Owner	13%	5,881,879	$6,470,066	—	31 Mar 2026	13F 3/4/5
RENAISSANCE TECHNOLOGIES LLC	13F	Company	1%	473,442	$525,521	—	31 Mar 2026	13F
Parkman Healthcare Partners LLC	13F	Company	0.63%	288,670	$320,424	—	31 Mar 2026	13F
CITADEL ADVISORS LLC	13F	Company	0.54%	245,577	$272,590	—	31 Mar 2026	13F
Seven Fleet Capital Management LP	13F	Company	0.45%	205,542	$228,152	—	31 Mar 2026	13F
MARSHALL WACE, LLP	13F	Company	0.43%	195,780	$217,316	—	31 Mar 2026	13F
NORTHERN TRUST CORP	13F	Company	0.32%	146,854	$163,008	—	31 Mar 2026	13F
XTX Topco Ltd	13F	Company	0.29%	131,622	$146,100	—	31 Mar 2026	13F
Schonfeld Strategic Advisors LLC	13F	Company	0.12%	55,223	$61,296	—	31 Mar 2026	13F
SIGNATURE ESTATE & INVESTMENT ADVISORS LLC	13F	Company	0.1%	47,328	$52,534	—	31 Mar 2026	13F
HighTower Advisors, LLC	13F	Company	0.08%	36,830	$40,881	—	31 Mar 2026	13F
JANE STREET GROUP, LLC	13F	Company	0.07%	32,915	$36,536	—	31 Mar 2026	13F
DIADEMA PARTNERS LP	13F	Company	0.05%	23,260	$25,819	—	31 Mar 2026	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.05%	21,136	$23,460	—	31 Mar 2026	13F
Gem Investment Advisors, LLC	13F	Company	0.04%	19,135	$21,240	—	31 Mar 2026	13F
HRT FINANCIAL LP	13F	Company	0.03%	15,492	$17,000	—	31 Mar 2026	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.03%	12,000	$13,320	—	31 Mar 2026	13F
PNC FINANCIAL SERVICES GROUP, INC.	13F	Company	0.02%	10,000	$11,100	—	31 Mar 2026	13F
JPMORGAN CHASE & CO	13F	Company	0.02%	7,150	$7,150	—	31 Mar 2026	13F
Persistent Asset Partners Ltd	13F	Company	0.01%	5,881	$6,528	—	31 Mar 2026	13F
UBS Group AG	13F	Company	0.01%	3,212	$3,565	—	31 Mar 2026	13F
MORGAN STANLEY	13F	Company	0%	400	$444	—	31 Mar 2026	13F
GROUP ONE TRADING LLC	13F	Company	0%	51	$57	—	31 Mar 2026	13F
Caitong International Asset Management Co., Ltd	13F	Company	0%	20	$22	—	31 Mar 2026	13F
SBI Securities Co., Ltd.	13F	Company	0%	2	$2	—	31 Mar 2026	13F
Gerald M. Lieberman	3/4/5	Director	— mixed-class rows	406,668 mixed-class rows	$823,723	—	01 Jan 2026	3/4/5
Miranda Jayne Toledano	3/4/5	Chief Executive Officer, Director	— mixed-class rows	926,575 mixed-class rows	$772,186	+$19,912	29 Dec 2025	3/4/5
Phillip Schwartz	3/4/5	President of R&D, Director	— class O/S missing	607,410	$601,336	—	20 Jan 2022	3/4/5
Sean Ellis	3/4/5	Director	— mixed-class rows	221,603 mixed-class rows	$231,360	+$34,620	05 Mar 2026	3/4/5
Gregory Burshtein	3/4/5	Chief of R&D	— mixed-class rows	389,033 mixed-class rows	$209,826	—	07 May 2026	3/4/5
Dana Yaacov-Garbeli	3/4/5	Chief Financial Officer	— mixed-class rows	301,441 mixed-class rows	$190,299	—	07 May 2026	3/4/5
Yonatan Malca	3/4/5	Director	— mixed-class rows	110,921 mixed-class rows	$185,024	—	01 Jan 2026	3/4/5
Hillel Galitzer	3/4/5	Chief Operating Officer	— mixed-class rows	263,566 mixed-class rows	$181,558	—	07 May 2026	3/4/5
Gerald M. Ostrov	3/4/5	Director	— mixed-class rows	109,162 mixed-class rows	$180,820	—	01 Jan 2026	3/4/5
Ramesh Ratan	3/4/5	U.S.based CFO	— class O/S missing	10,000	$9,900	—	19 Jan 2022	3/4/5
Spiros Jamas	3/4/5	Chief Executive Officer	— class O/S missing	10,000	$9,900	—	18 Jan 2022	3/4/5
Roger Garceau	3/4/5	Director	— class O/S missing	108,333	—	—	01 Jan 2024	3/4/5
Ron Mayron	3/4/5	Director	— class O/S missing	108,333	—	—	01 Jan 2024	3/4/5
Arthur C. Santora II	3/4/5	Chief Medical Officer	— class O/S missing	35,000	—	—	24 Apr 2023	3/4/5
Haya Taitel	3/4/5	Director	— class O/S missing	33,505	—	+$11,100	10 Feb 2026	3/4/5

Recent Insider Transactions by Companies or Individuals for Entera Bio Ltd.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
Hillel Galitzer	ENTX	Ordinary Shares, par value NIS 0.0000769 per share	Award	80.6%			72,993	163,566	07 May 2026	Direct
Dana Yaacov-Garbeli	ENTX	Ordinary Shares, par value NIS 0.0000769 per share	Award	51.6%			58,394	171,441	07 May 2026	By A2Z Counseling Ltd.
Gregory Burshtein	ENTX	Ordinary Shares, par value NIS 0.0000769 per share	Award	86.4%			87,591	189,033	07 May 2026	Direct
Geno J. Germano	ENTX	Ordinary Shares, par value NIS 0.0000769 per share	Purchase	100%	$26,000	$1.30	20,000	40,000	09 Mar 2026	Direct
Sean Ellis	ENTX	Ordinary Shares, par value NIS 0.0000769 per share	Purchase	5.61%	$12,300	$1.23	10,000	188,098	05 Mar 2026	Direct
Steven D. Rubin	ENTX	Ordinary Shares, par value NIS 0.0000769 per share	Purchase	50%	$7,450	$1.49	5,000	15,000	12 Feb 2026	Direct
Haya Taitel	ENTX	Ordinary Shares, par value NIS 0.0000769 per share	Purchase		$11,100	$1.48	7,500	$98,479	10 Feb 2026	Direct
Geno J. Germano	ENTX	Ordinary Shares, par value NIS 0.0000769 per share	Purchase		$29,800	$1.49	20,000	$20,000	10 Feb 2026	Direct
Steven D. Rubin	ENTX	Ordinary Shares, par value NIS 0.0000769 per share	Purchase		$12,000	$1.20	10,000	10,000	09 Feb 2026	Direct
Sean Ellis	ENTX	Ordinary Shares, par value NIS 0.0000769 per share	Purchase	11.2%	$22,320	$1.24	18,000	178,098	09 Feb 2026	Direct
Haya Taitel	ENTX	Ordinary Shares, par value NIS 0.0000769 per share	Award	40.7%			26,329	90,979	01 Jan 2026	Direct
Haya Taitel	ENTX	Stock Option (right to buy)	Award				33,505	33,505	01 Jan 2026	Direct
Gerald M. Ostrov	ENTX	Ordinary Shares, par value NIS 0.0000769 per share	Award	61.2%			28,721	75,657	01 Jan 2026	Direct
Gerald M. Ostrov	ENTX	Stock Option (right to buy)	Award				33,505	33,505	01 Jan 2026	Direct
Sean Ellis	ENTX	Ordinary Shares, par value NIS 0.0000769 per share	Award	18.8%			25,371	160,098	01 Jan 2026	Direct
Sean Ellis	ENTX	Stock Option (right to buy)	Award				33,505	33,505	01 Jan 2026	Direct
Yonatan Malca	ENTX	Ordinary Shares, par value NIS 0.0000769 per share	Award	63.8%			30,157	77,416	01 Jan 2026	Direct
Yonatan Malca	ENTX	Stock Option (right to buy)	Award				33,505	33,505	01 Jan 2026	Direct
Gerald M. Lieberman	ENTX	Ordinary Shares, par value NIS 0.0000769 per share	Award	12.8%			38,294	338,454	01 Jan 2026	Direct
Gerald M. Lieberman	ENTX	Stock Option (right to buy)	Award				33,505	33,505	01 Jan 2026	Direct
Miranda Jayne Toledano	ENTX	Ordinary Shares, par value NIS 0.0000769 per share	Purchase	2.65%	$19,912	$1.81	11,000	426,575	29 Dec 2025	Direct
Miranda Jayne Toledano	ENTX	Ordinary Shares, par value NIS 0.0000769 per share	Award	76.9%			180,702	415,575	16 Jul 2025	Direct
Miranda Jayne Toledano	ENTX	Stock Option (Right to Buy)	Award				500,000	500,000	16 Jul 2025	Direct
Gregory Burshtein	ENTX	Ordinary Shares, par value NIS 0.0000769 per share	Award	35%			26,316	101,442	16 Jul 2025	Direct
Gregory Burshtein	ENTX	Stock Option (right to buy)	Award				200,000	200,000	16 Jul 2025	Direct
Dana Yaacov-Garbeli	ENTX	Ordinary Shares, par value NIS 0.0000769 per share	Award	30.3%			26,316	113,047	16 Jul 2025	By A2Z Counseling Ltd.
Dana Yaacov-Garbeli	ENTX	Stock Option (right to buy)	Award				130,000	130,000	16 Jul 2025	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.